Vancouver Sun

Breakthrou­gh: 5 questions about the new vaccine

The world has been waiting years for an effective Ebola vaccine and this is a huge step in that direction. But there are still many unanswered questions.

-

Q How long will the vaccine’s protection last?

A The trial shows this vaccine — called rVSVZEBOV — is likely going to be very useful as a tool to snuff out outbreaks.

Only one dose of vaccine is needed and protection kicks in fast, within about six days. Those are two great characteri­stics when you are trying to stop the spread of a deadly virus.

But no one yet knows how long that protection will last. Some of the people who were vaccinated will have to be followed for years to see whether and how soon their immunity starts to wear off.

Q What does this mean to the other Ebola vaccines in developmen­t?

A Most vaccines target diseases that are common. They cost hundreds of millions of dollars to develop, but the expense is recouped through ongoing annual sales.

That won’t be the situation with an Ebola vaccine. Despite the massive West African outbreak, Ebola is a rare disease. At this point no country would consider vaccinatin­g all its children against Ebola, for example. It wouldn’t make economic sense.

So while there are quite a few other experiment­al Ebola vaccines at various stages of developmen­t the reality is most of them won’t make it over the finish line.

Q Is there room for any other Ebola vaccines, then?

A Sure. The working assumption is some of the other candidates might provide longer lasting protection, though they will need to be given in several doses over a period of months.

That kind of delivery strategy doesn’t work well for outbreak control. But it could be really useful to protect health care workers in places where Ebola crops up from time to time. Q Can this vaccine be used to stop all future Ebola outbreaks?

A Probably not. There are five known strains of Ebola, three of which have caused large outbreaks in people. This vaccine protects against Ebola Zaire. Studies in non-human primates suggest a vaccine that protects against Ebola Zaire won’t protect against the Sudan or Bundibugyo strains, and vice versa. So vaccines that protect against them will need to be made as well.

Q Will this vaccine help to finally end the lingering West African outbreak?

A That’s a real possibilit­y. The trial in Guinea will now offer vaccine to contacts of any new Ebola cases. And if they haven’t already started, talks will soon be underway with the government of Sierra Leone to see if they want to use ring vaccinatio­n. Guinea and Sierra Leone are the only two countries recording cases of Ebola right now.

 ?? CELLOU BINANI/AFP/GETTY IMAGES FILES ?? A woman gets vaccinated at a health centre in Conakry, Guinea, during the first clinical trials of the rVSV-ZEBOV vaccine against the Ebola virus in March.
CELLOU BINANI/AFP/GETTY IMAGES FILES A woman gets vaccinated at a health centre in Conakry, Guinea, during the first clinical trials of the rVSV-ZEBOV vaccine against the Ebola virus in March.

Newspapers in English

Newspapers from Canada